Cellular Immuno-Oncology 2.0
Dr Mark Lowdell, Dir. Cellular Therapeutics, UCL
With Novartis and Kite, busying themselves with the roll out of Kymriah and Yescarta, it is timely to examine the latest progress in addressing long-standing manufacturing and supply chain-related challenges facing the cellular immunotherapy field, particularly at clinical and commercial scales.
- Assessing the latest strategic and technical solutions for autologous cellular immunotherapy product development and scalable manufacture (including automation technology)
- Next-generation CAR-T platforms, TCRs & combination approaches and enabling technologies
- Focus on the convergence of immuno-oncology and gene editing
- Progressing allogeneic cancer immunotherapy